Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (515) 515
Book Review (6) 6
Publication (4) 4
Book Chapter (3) 3
Book / eBook (2) 2
Conference Proceeding (2) 2
Patent (1) 1
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (332) 332
science & technology (313) 313
life sciences & biomedicine (311) 311
female (306) 306
oncology (262) 262
breast cancer (204) 204
middle aged (186) 186
breast neoplasms - drug therapy (185) 185
adult (162) 162
medical sciences (153) 153
biological and medical sciences (151) 151
aged (141) 141
breast neoplasms - pathology (127) 127
tumors (125) 125
chemotherapy (107) 107
chemotherapy, adjuvant (103) 103
antineoplastic combined chemotherapy protocols - therapeutic use (97) 97
gynecology. andrology. obstetrics (91) 91
disease-free survival (86) 86
mammary gland diseases (86) 86
prognosis (81) 81
treatment outcome (80) 80
cancer (79) 79
breast neoplasms - mortality (70) 70
breast neoplasms - surgery (65) 65
hematology, oncology and palliative medicine (62) 62
antineoplastic agents, hormonal - therapeutic use (60) 60
antineoplastic agents (59) 59
breast neoplasms - metabolism (53) 53
breast neoplasms - therapy (53) 53
clinical trials (52) 52
care and treatment (51) 51
pharmacology. drug treatments (51) 51
neoplasm staging (49) 49
lymphatic metastasis (46) 46
tamoxifen - therapeutic use (46) 46
research (45) 45
tamoxifen (45) 45
abridged index medicus (44) 44
follow-up studies (43) 43
medicine & public health (40) 40
receptors, estrogen - metabolism (39) 39
aged, 80 and over (38) 38
retrospective studies (37) 37
combined modality therapy (36) 36
general & internal medicine (36) 36
health aspects (36) 36
medicine, general & internal (36) 36
survival analysis (35) 35
adjuvant treatment (34) 34
cyclophosphamide - administration & dosage (34) 34
drug therapy (33) 33
fluorouracil - administration & dosage (33) 33
male (33) 33
risk factors (33) 33
tamoxifen - administration & dosage (32) 32
antineoplastic agents - therapeutic use (31) 31
obstetrics & gynecology (31) 31
postmenopause (31) 31
quality of life (31) 31
receptor, erbb-2 - metabolism (31) 31
antineoplastic combined chemotherapy protocols - adverse effects (30) 30
drug administration schedule (30) 30
analysis (29) 29
randomized controlled trials as topic (29) 29
premenopause (28) 28
antineoplastic combined chemotherapy protocols - administration & dosage (27) 27
endocrine therapy (27) 27
receptors, estrogen - analysis (27) 27
survival rate (27) 27
antineoplastic agents, hormonal - adverse effects (26) 26
breast neoplasms - genetics (26) 26
clinical trials as topic (26) 26
proportional hazards models (26) 26
menopause (25) 25
surgery (25) 25
cancer patients (24) 24
immunohistochemistry (24) 24
mastectomy (24) 24
methotrexate - administration & dosage (24) 24
oncology, experimental (24) 24
receptors, progesterone - metabolism (24) 24
kaplan-meier estimate (23) 23
tamoxifen - adverse effects (23) 23
breast neoplasms - chemistry (22) 22
estrogen (22) 22
trastuzumab (22) 22
antineoplastic agents, hormonal - administration & dosage (21) 21
cancer therapies (21) 21
nitriles - therapeutic use (21) 21
triazoles - therapeutic use (21) 21
antineoplastic agents - adverse effects (19) 19
breast neoplasms (18) 18
cancer and oncology (18) 18
cancer och onkologi (18) 18
double-blind method (18) 18
postmenopausal women (18) 18
aromatase inhibitors - therapeutic use (17) 17
breast neoplasms - diagnosis (17) 17
medical research (17) 17
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text An interview with Dr. Aron Goldhirsch
by Goldhirsch, Aron
European journal of cancer (1990), ISSN 0959-8049, 09/2002, Volume 38, Issue 14, pp. 1814 - 1814
Life Sciences & Biomedicine | Oncology | Science & Technology | Career Mobility | Medical Oncology | Female | Research | Breast Neoplasms | Humans | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
by Cameron, David, Prof and Piccart-Gebhart, Martine J, PhD and Gelber, Richard D, PhD and Procter, Marion, PhD and Goldhirsch, Aron, MD and de Azambuja, Evandro, MD and Castro, Gilberto, MD and Untch, Michael, MD and Smith, Ian, MD and Gianni, Luca, MD and Baselga, Jose, MD and Al-Sakaff, Nedal, PhD and Lauer, Sabine, PhD and McFadden, Eleanor, MA and Leyland-Jones, Brian, MBBS and Bell, Richard, MBBS and Dowsett, Mitch, PhD and Jackisch, Christian, MD and Herceptin Adjuvant (HERA) Trial Study Team and Herceptin Adjuvant HERA Trial
The Lancet (British edition), ISSN 0140-6736, 2017, Volume 389, Issue 10075, pp. 1195 - 1205
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antineoplastic Agents, Immunological - administration & dosage | Trastuzumab - therapeutic use | Drug Administration Schedule | Follow-Up Studies | Biomarkers, Tumor - analysis | Humans | Middle Aged | Kaplan-Meier Estimate | Trastuzumab - adverse effects | Treatment Outcome | Trastuzumab - administration & dosage | Breast Neoplasms - drug therapy | Antineoplastic Agents, Immunological - adverse effects | Breast Neoplasms - chemistry | Antineoplastic Agents, Immunological - therapeutic use | Breast Neoplasms - pathology | Chemotherapy, Adjuvant - methods | Adult | Female | Aged | Receptor, ErbB-2 - analysis | Heart Diseases - chemically induced | Antimitotic agents | Medical colleges | Analysis | Adjuvant treatment | Monoclonal antibodies | Breast cancer | Antineoplastic agents | Cancer | Heart | Medical research | Laboratories | Toxicity | Health risks | Clinical trials | Mammography | Radiation therapy | Cancer therapies | Patients | Survival | ErbB-2 protein | Incidence | Chemotherapy | Motivation | Failure analysis | Surgery | Informed consent | Heart diseases | Trastuzumab | Schedules | Clinical outcomes | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
by Conforti, Fabio and Pala, Laura and Bagnardi, Vincenzo and De Pas, Tommaso and Martinetti, Marco and Viale, Giuseppe and Gelber, Richard D and Goldhirsch, Aron
The lancet oncology, ISSN 1470-2045, 06/2018, Volume 19, Issue 6, pp. 737 - 746
Life Sciences & Biomedicine | Oncology | Science & Technology | Cancer patients | Care and treatment | Analysis | Immunotherapy | Metastasis | Drug therapy | Lung cancer, Non-small cell | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
by Gianni, Luca, Prof and Dafni, Urania, Prof and Gelber, Richard D, Prof and Azambuja, Evandro, PhD and Muehlbauer, Susanne, PhD and Goldhirsch, Aron, Prof and Untch, Michael, Prof and Smith, Ian, Prof and Baselga, José, Prof and Jackisch, Christian, Prof and Cameron, David, Prof and Mano, Max, MD and Pedrini, José Luiz, MD and Veronesi, Andrea, Prof and Mendiola, Cesar, MD and Pluzanska, Anna, Prof and Semiglazov, Vladimir, MD and Vrdoljak, Eduard, MD and Eckart, Michael J, MD and Shen, Zhenzhou, Prof and Skiadopoulos, George, MSci and Procter, Marion, MSci and Pritchard, Kathleen I, MD and Piccart-Gebhart, Martine J, PhD and Bell, Richard, MBBS and for the Herceptin Adjuvant (HERA) Trial Study Team and Herceptin Adjuvant HERA Trial Stud and Herceptin Adjuvant (HERA) Trial Study Team
The lancet oncology, ISSN 1470-2045, 2011, Volume 12, Issue 3, pp. 236 - 244
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Combined Modality Therapy | Breast Neoplasms - drug therapy | Breast Neoplasms - metabolism | Randomized Controlled Trials as Topic | Breast Neoplasms - therapy | Antibodies, Monoclonal, Humanized | Breast Neoplasms - pathology | Survival Analysis | Adult | Female | Receptor, ErbB-2 | Chemotherapy, Adjuvant | Trastuzumab | Antimitotic agents | Care and treatment | Epidermal growth factor | Adjuvant treatment | Cameron, David (British prime minister) | Breast cancer | Antineoplastic agents | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Personalized adjuvant therapies: Lessons from the past. The opening address by the St. Gallen 2013 award recipient
by Goldhirsch, Aron
Breast (Edinburgh), ISSN 0960-9776, 08/2013, Volume 22, Issue 2, pp. S3 - S7
Primary Breast Cancer | St. Gallen Breast Cancer Consensus | Breast Cancer: Optimal Primary Therapy | Breast Cancer Treatment Guidelines | Oncology | Life Sciences & Biomedicine | Obstetrics & Gynecology | Science & Technology | Breast Neoplasms - surgery | Triazoles - adverse effects | Prognosis | Humans | Middle Aged | Mastectomy - methods | Neoplasm Recurrence, Local - mortality | Neoplasm Recurrence, Local - pathology | Antineoplastic Agents, Hormonal - adverse effects | Antineoplastic Agents, Hormonal - therapeutic use | Postmenopause | Adult | Female | Chemotherapy, Adjuvant | Triazoles - therapeutic use | Premenopause | Risk Assessment | Neoplasm Recurrence, Local - therapy | Awards and Prizes | Treatment Outcome | Breast Neoplasms - drug therapy | Consensus Development Conferences as Topic | Switzerland | Randomized Controlled Trials as Topic | Disease-Free Survival | Breast Neoplasms - genetics | Tamoxifen - therapeutic use | Genes, erbB-2 - genetics | Survival Analysis | Breast Neoplasms - mortality | Aged | Tamoxifen - adverse effects | Nitriles - adverse effects | Precision Medicine - methods | Nitriles - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Ethnicity-based differences in breast cancer features and responsiveness to CDK4/6 inhibitors combined with endocrine therapy
by Pala, Laura and Conforti, Fabio and Goldhirsch, Aron
The lancet oncology, ISSN 1470-2045, 03/2020, Volume 21, Issue 3, pp. e130 - e130
Life Sciences & Biomedicine | Oncology | Science & Technology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Neoadjuvant chemotherapy for breast cancer: any progress?
by Colleoni, Marco and Goldhirsch, Aron
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 2, pp. 131 - 132
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Female | Neoadjuvant Therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - drug therapy | Humans | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials
by Bernhard, Jürg, Dr and Luo, Weixiu, MD and Ribi, Karin, PhD and Colleoni, Marco, MD and Burstein, Harold J, MD and Tondini, Carlo, MD and Pinotti, Graziella, MD and Spazzapan, Simon, MD and Ruhstaller, Thomas, MD and Puglisi, Fabio, MD and Pavesi, Lorenzo, MD and Parmar, Vani, MBBS and Regan, Meredith M, ScD and Pagani, Olivia, MD and Fleming, Gini F, MD and Francis, Prudence A, MD and Price, Karen N, BS and Coates, Alan S, MD and Gelber, Richard D, PhD and Goldhirsch, Aron, MD and Walley, Barbara A, MD
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 7, pp. 848 - 858
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Follow-Up Studies | Humans | Middle Aged | Dose-Response Relationship, Drug | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Invasiveness - pathology | Antineoplastic Agents, Hormonal - therapeutic use | Adult | Female | Ovary - drug effects | Chemotherapy, Adjuvant | Drug Administration Schedule | Risk Assessment | Administration, Oral | Early Detection of Cancer | Self Report | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - pathology | Tamoxifen - therapeutic use | Premenopause - physiology | Survival Analysis | Quality of Life | Breast Neoplasms - mortality | Tamoxifen - adverse effects | Neoplasm Staging | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Personalized adjuvant therapies: Lessons from the past
by Goldhirsch, Aron
Breast (Edinburgh), ISSN 0960-9776, 2013, Volume 22, pp. S3 - S7
Hematology, Oncology and Palliative Medicine | Primary Breast Cancer | St. Gallen Breast Cancer Consensus | Breast Cancer: Optimal Primary Therapy | Breast Cancer Treatment Guidelines | Chemotherapy | Postmenopausal women | Tamoxifen | Steroid hormones | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Patterns of Recurrence and Outcome According to Breast Cancer Subtypes in Lymph Node–Negative Disease: Results From International Breast Cancer Study Group Trials VIII and IX
by Otto Metzger-Filho and Zhuoxin Sun and Giuseppe Viale and Karen N. Price and Diana Crivellari and Raymond D. Snyder and Richard D. Gelber and Monica Castiglione-Gertsch and Alan S. Coates and Aron Goldhirsch and Fatima Cardoso
Journal of clinical oncology, ISSN 0732-183X, 09/2013, Volume 31, Issue 25, pp. 3083 - 3090
Life Sciences & Biomedicine | Oncology | Science & Technology | Gynecology. Andrology. Obstetrics | Mammary gland diseases | Biological and medical sciences | Multiple tumors. Solid tumors. Tumors in childhood (general aspects) | Medical sciences | Tumors | Breast Neoplasms - classification | Humans | Middle Aged | Treatment Outcome | Lymphatic Metastasis | Receptors, Estrogen - analysis | Incidence | Receptors, Progesterone - analysis | Breast Neoplasms - chemistry | Breast Neoplasms - pathology | Adult | Breast Neoplasms - mortality | Female | Aged | Neoplasm Recurrence, Local - epidemiology | Receptor, ErbB-2 - analysis | Index Medicus | Bc5 | ORIGINAL REPORTS | Bc7
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
by Francis, Prudence A and Regan, Meredith M and Fleming, Gini F and Láng, István and Ciruelos, Eva and Bellet, Meritxell and Bonnefoi, Hervé R and Climent, Miguel A and Da Prada, Gian Antonio and Burstein, Harold J and Martino, Silvana and Davidson, Nancy E and Geyer, Charles E and Walley, Barbara A and Coleman, Robert and Kerbrat, Pierre and Buchholz, Stefan and Ingle, James N and Winer, Eric P and Rabaglio-Poretti, Manuela and Maibach, Rudolf and Ruepp, Barbara and Giobbie-Hurder, Anita and Price, Karen N and Colleoni, Marco and Viale, Giuseppe and Coates, Alan S and Goldhirsch, Aron and Gelber, Richard D and Int Breast Canc Study Grp and SOFT Investigators and International Breast Cancer Study Group
The New England journal of medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 5, pp. 436 - 446
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Breast Neoplasms - surgery | Premenopause | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Breast Neoplasms - drug therapy | Antineoplastic Agents, Hormonal - adverse effects | Disease-Free Survival | Aromatase Inhibitors - adverse effects | Breast Neoplasms - radiotherapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antineoplastic Agents, Hormonal - therapeutic use | Tamoxifen - therapeutic use | Mastectomy | Adult | Female | Androstadienes - therapeutic use | Chemotherapy, Adjuvant | Tamoxifen - adverse effects | Androstadienes - adverse effects | Aromatase Inhibitors - therapeutic use | Chemotherapy | Womens health | Invasiveness | Estrogens | Population studies | Breast cancer | Reproductive system | Tamoxifen | Drug therapy | Survival | Patients | Statistical analysis | Endocrine therapy | Radiation therapy | Cancer therapies | Survival analysis | Health risk assessment | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
by Pagani, Olivia and Regan, Meredith M and Walley, Barbara A and Fleming, Gini F and Colleoni, Marco and Láng, István and Gomez, Henry L and Tondini, Carlo and Burstein, Harold J and Perez, Edith A and Ciruelos, Eva and Stearns, Vered and Bonnefoi, Hervé R and Martino, Silvana and Geyer, Charles E and Pinotti, Graziella and Puglisi, Fabio and Crivellari, Diana and Ruhstaller, Thomas and Winer, Eric P and Rabaglio-Poretti, Manuela and Maibach, Rudolf and Ruepp, Barbara and Giobbie-Hurder, Anita and Price, Karen N and Bernhard, Jürg and Luo, Weixiu and Ribi, Karin and Viale, Giuseppe and Coates, Alan S and Gelber, Richard D and Goldhirsch, Aron and Francis, Prudence A and TEXT SOFT Investigators Int Breast and International Breast Cancer Study Group and TEXT and SOFT Investigators
The New England journal of medicine, ISSN 0028-4793, 07/2014, Volume 371, Issue 2, pp. 107 - 118
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Gynecology. Andrology. Obstetrics | Mammary gland diseases | General aspects | Biological and medical sciences | Multiple tumors. Solid tumors. Tumors in childhood (general aspects) | Medical sciences | Tumors | Estradiol - blood | Breast Neoplasms - surgery | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Antineoplastic Agents, Hormonal - therapeutic use | Mastectomy | Adult | Female | Chemotherapy, Adjuvant | Aromatase Inhibitors - therapeutic use | Osteoporosis - chemically induced | Premenopause | Kaplan-Meier Estimate | Triptorelin Pamoate - adverse effects | Triptorelin Pamoate - therapeutic use | Breast Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - radiotherapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tamoxifen - therapeutic use | Quality of Life | Androstadienes - therapeutic use | Tamoxifen - adverse effects | Androstadienes - adverse effects | Care and treatment | Breast cancer | Research | Ovariectomy | Invasiveness | Estrogens | Radiation | Clinical trials | Data processing | Pituitary (anterior) | Gonadotropins | Tamoxifen | Survival | Patients | Clinical outcomes | Post-menopause | Chemotherapy | Aromatase | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights